Clinical Trials

Overview

About this study

There is agreement that several factors determine a person’s risk for diabetic retinopathy, namely hyperglycemia, diabetes duration, and systemic hypertension. There is also increasing evidence
supporting a genetic component in DR susceptibility given the heterogeneity of DR in patients with equally poor glycemic control. Several studies, including the Diabetes Control and Complications Trial, have provided evidence for a familial tendency toward DR development, independent of associated risk factors.7 107 Therefore, studies on the genetic risk factors related to diabetic retinopathy are of public health importance.

The DRCR.net is pursuing this genetics initiative to collect, store, analyze, and distribute genetic material with accompanying phenotypic information. The initiative will provide a unique opportunity to combine data from multiple populations, including the Type 1 and Type 2 diabetic populations in the US, to define genetic factors that confer risk for development and progression of diabetic retinopathy, and response to therapeutic intervention. 

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Participating Mayo Clinic locations

More information